BioTime Announces Management Changes Concurrent With Participation at 2019 J.P. Morgan Healthcare Conference and 2019 Biotech...
January 04 2019 - 8:00AM
BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology
company focused on degenerative diseases, today announced the
appointment of Brandi L. Roberts, M.B.A. as Chief Financial Officer
and Senior Vice President, Finance, effective January 7, 2019. Ms.
Roberts brings more than 23 years of public accounting and finance
experience, including 20 years at publicly traded pharmaceutical,
medical technology, and life science companies. Ms. Roberts
will join BioTime’s CEO, Brian Culley, and other members of
BioTime’s executive team as they host institutional investor and
partnering meetings around the 2019 J.P. Morgan Healthcare
Conference and the 2019 Biotech Showcase.
"I’m excited to welcome Brandi to the BioTime
team during this critical period in which we increase the focus on
our clinical-stage product candidates and improve our business
structure through recently-announced and pending transactions
involving our affiliated companies, AgeX (NYSE American: AGE) and
Asterias (NYSE American: AST),” stated Brian M. Culley, Chief
Executive Officer of BioTime. “Brandi's extensive experience and
leadership at publicly-traded clinical and commercial-stage
companies, combined with her business acumen and operational
oversight, will be integral as we position BioTime to become a
leading cell therapy company, advance our product candidates, and
engage with the patient and advocacy communities which we seek to
serve. I also want to thank Russell Skibsted, our departing CFO,
for his many contributions to BioTime."
Most recently, Ms. Roberts served as Chief
Financial Officer and Corporate Secretary of REVA Medical, Inc., a
medical device company focused on the development of bioresorbable
polymers for vascular applications. Prior to REVA Medical, Ms.
Roberts served as Chief Financial Officer at Mast Therapeutics,
Inc., a publicly traded US-based biopharmaceutical company, from
January 2013 to April 2017, having served as the Company’s Senior
Vice President, Finance from March 2011 to January 2013.
Previously, she held senior positions at Alphatec Spine, Artes
Medical, Stratagene and Pfizer. Ms. Roberts is a
certified public accountant with the State of California and
received her B.S. in Business Administration from the University of
Arizona and her M.B.A. from the University of San Diego. She also
currently serves as Chair of the Southern California Chapter of the
Association of Bioscience Financial Officers.
The annual J.P. Morgan Healthcare Conference is
the largest and most informative healthcare investment symposium in
the industry, bringing together industry leaders, emerging
fast-growth companies, innovative technology creators, and members
of the investment community in San Francisco, CA. Interested
parties may follow @jpmorgan on Twitter and use #JPM2019
for the latest meeting updates. The 2019 Biotech Showcase is an
investor and networking conference devoted to providing private and
public biotechnology and life sciences companies with an
opportunity to present to, and meet with, investors and executives
in one place during the course of the 37th Annual J.P. Morgan
Annual Healthcare Conference. Interested parties may
follow @EBDGroup on Twitter and use #BiotechShowcase for
the latest updates.
About BioTime, Inc.
BioTime is a clinical-stage biotechnology company focused on
the development and commercialization of novel therapies for the
treatment of degenerative diseases. BioTime’s pipeline is based on
two platform technologies which encompass cell replacement and
cell/drug delivery. BioTime’s lead cell replacement product
candidate is OpRegen®, a retinal pigment epithelium transplant
therapy in Phase 2 development for the treatment of dry age-related
macular degeneration, the leading cause of blindness in the
developed world. BioTime’s lead cell delivery clinical program is
Renevia®, an investigational medical device being developed as an
alternative for whole adipose tissue transfer procedures.
BioTime common stock is traded on the NYSE American and TASE
under the symbol BTX. For more information, please
visit www.biotime.com or connect with the company on
Twitter, LinkedIn, Facebook, YouTube, and Google+. To
receive ongoing BioTime corporate communications, please
click on the following link to join the Company’s email alert
list: http://news.biotime.com.
Additional Information and Where to Find
It This communication is being made in respect of the
proposed business combination involving BioTime, Inc. and Asterias
Biotherapeutics, Inc. In connection with the proposed transaction,
BioTime and Asterias plan to file documents with the U.S.
Securities and Exchange Commission (the “SEC”), including the
filing by BioTime of a Registration Statement on Form S-4
containing a Joint Proxy Statement/Prospectus and each of BioTime
and Asterias plan to file with the SEC other documents regarding
the proposed transaction. INVESTORS AND SECURITY HOLDERS OF BIOTIME
AND ASTERIAS ARE URGED TO CAREFULLY READ THE JOINT PROXY
STATEMENT/PROSPECTUS (WHEN AVAILABLE) AND OTHER DOCUMENTS FILED
WITH THE SEC BY BIOTIME AND ASTERIAS BECAUSE THEY WILL CONTAIN
IMPORTANT INFORMATION ABOUT THE PROPOSED TRANSACTION. Investors and
security holders may obtain free copies of these documents (when
they are available) and other documents filed with the SEC at the
SEC’s web site at www.sec.gov and by contacting BioTime Investor
Relations at (510) 871-4188 or Asterias Investor Relations at (510)
456-3892. Investors and security holders may obtain free copies of
the documents filed with the SEC on BioTime’s website at
www.biotimeinc.com or Asterias’ website at
www.asteriasbiotherapeutics.com or the SEC’s website at
www.sec.gov. BioTime, Asterias and their respective directors and
executive officers may be deemed participants in the solicitation
of proxies with respect to the proposed transaction. Information
regarding the interests of these directors and executive officers
in the proposed transaction will be included in the Joint Proxy
Statement/Prospectus described above. Additional information
regarding the directors and executive officers of BioTime is also
included in BioTime’s proxy statement for its 2018 Annual Meeting
of Shareholders, which was filed with the SEC on March 29, 2018,
and additional information regarding the directors and executive
officers of Asterias is also included in Asterias’ proxy statement
for its 2018 Annual Meeting of Stockholders, which was filed with
the SEC on April 30, 2018, respectively.
No Offer or Solicitation This
document does not constitute an offer to sell or the solicitation
of an offer to buy any securities or a solicitation of any vote or
approval nor shall there be any sale of securities in any
jurisdiction in which such offer, solicitation or sale would be
unlawful prior to registration or qualification under the
securities laws of any such jurisdiction. No offering of securities
shall be made except by means of a prospectus meeting the
requirements of Section 10 of the Securities Act of 1933, as
amended.
Forward-Looking Statements
Certain statements in this communication, including statements
relating to the proposed merger between BioTime and Asterias and
the combined company’s future financial condition performance and
operating results, strategy and plans, including the design, status
, funding and timing of the clinical trials and further development
and potential of the product candidates are “forward-looking
statements” within the meaning of the Private Securities Litigation
Reform Act of 1995 giving BioTime’s and Asterias’ expectations or
predictions of future financial or business performance or
conditions. These forward-looking statements are subject to
numerous assumptions, risks and uncertainties which change over
time. Forward-looking statements speak only as of the date they are
made and we assume no duty to update forward-looking statements. In
addition to factors previously disclosed in BioTime’s and Asterias’
reports filed with the SEC and those identified elsewhere in this
communication, the following factors, among others, could cause
actual results to differ materially from forward-looking statements
and historical performance: the ability to meet closing conditions
to the proposed merger, including requisite approval by BioTime’s
shareholders and Asterias’ stockholders, on a timely basis or at
all; delay in closing the proposed merger; the ultimate outcome and
results of integrating the operations of BioTime and Asterias and
the ultimate ability to realize synergies and other benefits;
business disruption following the proposed merger; the availability
and access, in general, of funds to fund operations and necessary
capital expenditures. More information on potential factors that
could affect our results is included from time to time in the SEC
filings and reports of BioTime and Asterias, including the risks
identified under the sections captioned “Risk Factors” in BioTime’s
quarterly report on Form 10-Q filed with the SEC on November 8,
2018 and Asterias’ annual report on Form 10-K for the year ended
December 31, 2017 filed with the SEC on March 15, 2018, and
Asterias’ quarterly report on Form 10-Q for the quarter ended
September 30, 2018, which Asterias filed on November 9, 2018.
BioTime Inc. IRIoana C.
Hone(ir@biotimeinc.com)(510) 871-4188
Solebury Trout IRGitanjali Jain Ogawa
(Gogawa@troutgroup.com) (646) 378-2949
Asterias Biotherapeutics, Inc. (AMEX:AST)
Historical Stock Chart
From Jul 2024 to Aug 2024
Asterias Biotherapeutics, Inc. (AMEX:AST)
Historical Stock Chart
From Aug 2023 to Aug 2024